2024-05-20 21:04:09 ET
Amgen, Inc. (AMGN)
ATS and the Approval of IMDELLTRA Conference Call
May 20, 2024, 4:00 PM ET
Company Participants
Justin Claeys - Vice President of Investor Relations
Murdo Gordon - Executive Vice President, Global Commercial Operations
James Bradner - Executive Vice President, Research and Development
Jean-Charles Soria - Senior Vice President, Global Development Oncology
Susan Sweeney - Senior Vice President, Global Marketing, Access Capabilities
Primal Kaur - Vice President, Global Development, Inflammation
Conference Call Participants
Mohit Bansal - Wells Fargo
Matt Phipps - William Blair
Carter Gould - Barclays
Michael Yee - Jefferies
Matthew Dellatorre - Goldman Sachs
Evan Seigerman - BMO Capital Markets
Geoff Meacham - Bank of America
James Shin - Deutsche Bank
Kripa Devarakonda - Truist Securities
Gary Nachman - Raymond James
Presentation
Operator
My name is Julianne and I'll be your conference facilitator today for Amgen's Conference Call Following The American Thoracic Society 2024 International Conference and the Approval of IMDELLTRA. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speakers' prepared remarks. [Operator Instructions]
I would now like to introduce Justin Claeys, Vice President of Investor Relations. Mr. Claeys, you may now begin.
Justin Claeys
Thank you, Julianne. Good afternoon and let me welcome everyone to the call. We have met with a number of investors over the past several weeks and have been reinforcing the breadth and depth of opportunities across the four pillars of our business and are glad to discuss several of those in more detail with you today. We will begin with prepared remarks from Murdo Gordon, Jay Bradner, Jean-Charles Soria, Susan Sweeney and Primal Kaur and we'll then open it up for Q&A.
Through the course of our discussion, we'll be making some forward-looking statements, which are qualified by our Safe Harbor statement and please note that actual results can vary materially.
Please also note that we will be presenting slides to accompany the discussion on the webcast and we'll make these available immediately after the call on the Investor Relations section of our website.
Let me now turn the call over to Murdo.
Murdo Gordon
Thanks, Justin. It's an exciting time here at Amgen. We're reaching many more patients around the world with our existing medicines and we're advancing a broad range of potential first-in-class medicines in our mid and late-stage pipeline.
We have great confidence that we're on a path to deliver attractive long-term growth through the end of the decade and beyond, not just with our obesity portfolio, but also from the breadth and depth of opportunities across our four therapeutic area pillars. General medicine, oncology, inflammation and rare disease, each of which have strong momentum and plenty of room to go....
Read the full article on Seeking Alpha
For further details see:
Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript)